Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
5,401
archived clinical trials in
Alzheimer Disease

Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease
A Randomized, Double-Blinded, Placebo-Controlled Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Alexian Brothers Neurosciences Institute
597
mi
from
Elk Grove Village, IL
Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease
A Randomized, Double-Blinded, Placebo-Controlled Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Alexian Brothers Neurosciences Institute
597
mi
from
Elk Grove Village, IL
Click here to add this to my saved trials
Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease
A Randomized, Double-Blinded, Placebo-Controlled Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
NNS Clinical Research, LLC
834
mi
from
Tucson, AZ
Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease
A Randomized, Double-Blinded, Placebo-Controlled Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
NNS Clinical Research, LLC
834
mi
from
Tucson, AZ
Click here to add this to my saved trials
Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease
A Randomized, Double-Blinded, Placebo-Controlled Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Stanford Univ Med Ctr
1329
mi
from
Stanford, CA
Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease
A Randomized, Double-Blinded, Placebo-Controlled Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Stanford Univ Med Ctr
1329
mi
from
Stanford, CA
Click here to add this to my saved trials
Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease
A Randomized, Double-Blinded, Placebo-Controlled Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Brain Matters Research
1293
mi
from
Delray Beach, FL
Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease
A Randomized, Double-Blinded, Placebo-Controlled Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Brain Matters Research
1293
mi
from
Delray Beach, FL
Click here to add this to my saved trials
Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease
A Randomized, Double-Blinded, Placebo-Controlled Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Neuropsychiatric Research Center of Southwest Florida
1204
mi
from
Fort Myers, FL
Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease
A Randomized, Double-Blinded, Placebo-Controlled Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Neuropsychiatric Research Center of Southwest Florida
1204
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease
A Randomized, Double-Blinded, Placebo-Controlled Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
MD Clinical Trials, Inc.
1314
mi
from
Hallandale Beach, FL
Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease
A Randomized, Double-Blinded, Placebo-Controlled Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
MD Clinical Trials, Inc.
1314
mi
from
Hallandale Beach, FL
Click here to add this to my saved trials
Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease
A Randomized, Double-Blinded, Placebo-Controlled Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Compass Research LLC
1141
mi
from
Orlando, FL
Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease
A Randomized, Double-Blinded, Placebo-Controlled Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Compass Research LLC
1141
mi
from
Orlando, FL
Click here to add this to my saved trials
Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease
A Randomized, Double-Blinded, Placebo-Controlled Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Infinity Clinical Research, LLC
1299
mi
from
Sunrise, FL
Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease
A Randomized, Double-Blinded, Placebo-Controlled Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Infinity Clinical Research, LLC
1299
mi
from
Sunrise, FL
Click here to add this to my saved trials
Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease
A Randomized, Double-Blinded, Placebo-Controlled Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
St. Louis Clinical Trials, LLC
403
mi
from
Saint Louis, MO
Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease
A Randomized, Double-Blinded, Placebo-Controlled Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
St. Louis Clinical Trials, LLC
403
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease
A Randomized, Double-Blinded, Placebo-Controlled Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
CRI Lifetree
1237
mi
from
Marlton, NJ
Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease
A Randomized, Double-Blinded, Placebo-Controlled Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
CRI Lifetree
1237
mi
from
Marlton, NJ
Click here to add this to my saved trials
Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease
A Randomized, Double-Blinded, Placebo-Controlled Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Advanced Memory Research Institute of NJ PC
1273
mi
from
Toms River, NJ
Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease
A Randomized, Double-Blinded, Placebo-Controlled Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Advanced Memory Research Institute of NJ PC
1273
mi
from
Toms River, NJ
Click here to add this to my saved trials
Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease
A Randomized, Double-Blinded, Placebo-Controlled Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Insight Clinical Trials, LLC
902
mi
from
Beachwood, OH
Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease
A Randomized, Double-Blinded, Placebo-Controlled Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Insight Clinical Trials, LLC
902
mi
from
Beachwood, OH
Click here to add this to my saved trials
Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease
A Randomized, Double-Blinded, Placebo-Controlled Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Brown Hospital
1424
mi
from
East Providence, RI
Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease
A Randomized, Double-Blinded, Placebo-Controlled Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Brown Hospital
1424
mi
from
East Providence, RI
Click here to add this to my saved trials
Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease
A Randomized, Double-Blinded, Placebo-Controlled Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Georgetown University Hospital
1127
mi
from
Washington,
Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease
A Randomized, Double-Blinded, Placebo-Controlled Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Georgetown University Hospital
1127
mi
from
Washington,
Click here to add this to my saved trials
Indiana University Dementia Screening Trial
Indiana University Dementia Screening Trial: The IU CHOICE Study
Status: Enrolling
Updated:  12/31/1969
IU Health-Primary Care Clinics
643
mi
from
Indianapolis, IN
Indiana University Dementia Screening Trial
Indiana University Dementia Screening Trial: The IU CHOICE Study
Status: Enrolling
Updated: 12/31/1969
IU Health-Primary Care Clinics
643
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Indiana University Dementia Screening Trial
Indiana University Dementia Screening Trial: The IU CHOICE Study
Status: Enrolling
Updated:  12/31/1969
Wishard Health Services-Primary Care Clinics
643
mi
from
Indianapolis, IN
Indiana University Dementia Screening Trial
Indiana University Dementia Screening Trial: The IU CHOICE Study
Status: Enrolling
Updated: 12/31/1969
Wishard Health Services-Primary Care Clinics
643
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Indiana University Dementia Screening Trial
Indiana University Dementia Screening Trial: The IU CHOICE Study
Status: Enrolling
Updated:  12/31/1969
IU Health Arnett Primary Care Clinics
613
mi
from
West Lafayette, IN
Indiana University Dementia Screening Trial
Indiana University Dementia Screening Trial: The IU CHOICE Study
Status: Enrolling
Updated: 12/31/1969
IU Health Arnett Primary Care Clinics
613
mi
from
West Lafayette, IN
Click here to add this to my saved trials
A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Banner Alzheimer'S Institute
851
mi
from
Phoenix, AZ
A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Banner Alzheimer'S Institute
851
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic
834
mi
from
Scottsdale, AZ
A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic
834
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Banner Sun Health Research Insitute
859
mi
from
Sun City, AZ
A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Banner Sun Health Research Insitute
859
mi
from
Sun City, AZ
Click here to add this to my saved trials
A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Pharmacology Research Inst
1179
mi
from
Encino, CA
A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Pharmacology Research Inst
1179
mi
from
Encino, CA
Click here to add this to my saved trials
A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Margolin Brain Institute
1204
mi
from
Fresno, CA
A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Margolin Brain Institute
1204
mi
from
Fresno, CA
Click here to add this to my saved trials
A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Univ of CA San Diego; Neurosciences Comp.Alzheimer's
1142
mi
from
La Jolla, CA
A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Univ of CA San Diego; Neurosciences Comp.Alzheimer's
1142
mi
from
La Jolla, CA
Click here to add this to my saved trials
A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
USC School of Medicine
1166
mi
from
Los Angeles, CA
A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
USC School of Medicine
1166
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
University of California at Los Angeles - UCLA
1177
mi
from
Los Angeles, CA
A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
University of California at Los Angeles - UCLA
1177
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Pharmacology Research Inst
1156
mi
from
Newport Beach, CA
A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Pharmacology Research Inst
1156
mi
from
Newport Beach, CA
Click here to add this to my saved trials
A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Pacific Neuroscience Med Grp
1214
mi
from
Oxnard, CA
A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Pacific Neuroscience Med Grp
1214
mi
from
Oxnard, CA
Click here to add this to my saved trials
A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Stanford University Medical Center
1330
mi
from
Palo Alto, CA
A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Stanford University Medical Center
1330
mi
from
Palo Alto, CA
Click here to add this to my saved trials
A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
University of California Davis Medical System
1281
mi
from
Sacramento, CA
A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
University of California Davis Medical System
1281
mi
from
Sacramento, CA
Click here to add this to my saved trials
A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Pacific Research Network - PRN
1142
mi
from
San Diego, CA
A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Pacific Research Network - PRN
1142
mi
from
San Diego, CA
Click here to add this to my saved trials
A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Uni of California San Francisco
1341
mi
from
San Francisco, CA
A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Uni of California San Francisco
1341
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Redwood Regional Medical Group, Inc.
1351
mi
from
Santa Rosa, CA
A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Redwood Regional Medical Group, Inc.
1351
mi
from
Santa Rosa, CA
Click here to add this to my saved trials
A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Yale University
1344
mi
from
New Haven, CT
A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Yale University
1344
mi
from
New Haven, CT
Click here to add this to my saved trials
A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Florida Atlantic University - College of Medicine
1297
mi
from
Boca Raton, FL
A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Florida Atlantic University - College of Medicine
1297
mi
from
Boca Raton, FL
Click here to add this to my saved trials
A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Meridien Research
1093
mi
from
Brooksville, FL
A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Meridien Research
1093
mi
from
Brooksville, FL
Click here to add this to my saved trials
A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Brain Matters Research
1293
mi
from
Delray Beach, FL
A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Brain Matters Research
1293
mi
from
Delray Beach, FL
Click here to add this to my saved trials
A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Miami Jewish Health Systems; Clinical Research
1319
mi
from
Miami, FL
A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Miami Jewish Health Systems; Clinical Research
1319
mi
from
Miami, FL
Click here to add this to my saved trials
A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Collier Neurologic Specialists
1232
mi
from
Naples, FL
A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Collier Neurologic Specialists
1232
mi
from
Naples, FL
Click here to add this to my saved trials
A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Axiom Clinical Research of Florida
1116
mi
from
Tampa, FL
A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Axiom Clinical Research of Florida
1116
mi
from
Tampa, FL
Click here to add this to my saved trials
A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Premiere Research Institute
1281
mi
from
West Palm Beach, FL
A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Premiere Research Institute
1281
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Dekalb Neurology Associates, LLC
805
mi
from
Decatur, GA
A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Dekalb Neurology Associates, LLC
805
mi
from
Decatur, GA
Click here to add this to my saved trials
A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Rush Alzheimer's Disease Cntr.
608
mi
from
Chicago, IL
A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Rush Alzheimer's Disease Cntr.
608
mi
from
Chicago, IL
Click here to add this to my saved trials
A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Alexian Brothers Neurosci Inst
596
mi
from
Elk Grove Village, IL
A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Alexian Brothers Neurosci Inst
596
mi
from
Elk Grove Village, IL
Click here to add this to my saved trials
A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Indiana Univ School Of Med
642
mi
from
Indianapolis, IN
A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Indiana Univ School Of Med
642
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Louisiana Research Associates, Inc.
700
mi
from
New Orleans, LA
A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Louisiana Research Associates, Inc.
700
mi
from
New Orleans, LA
Click here to add this to my saved trials
A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Hattiesburg Clinic
659
mi
from
Hattiesburg, MS
A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Hattiesburg Clinic
659
mi
from
Hattiesburg, MS
Click here to add this to my saved trials
A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic Lou Ruvo; Center for Brain Research
961
mi
from
Las Vegas, NV
A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic Lou Ruvo; Center for Brain Research
961
mi
from
Las Vegas, NV
Click here to add this to my saved trials
A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Memory Enhancement Center of America, Inc.
1283
mi
from
Eatontown, NJ
A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Memory Enhancement Center of America, Inc.
1283
mi
from
Eatontown, NJ
Click here to add this to my saved trials
A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
The Neurocognitive Institute, LLC
1254
mi
from
Mount Arlington, NJ
A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
The Neurocognitive Institute, LLC
1254
mi
from
Mount Arlington, NJ
Click here to add this to my saved trials
A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Empire Neurology, PC
1309
mi
from
Latham, NY
A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients With Mild to Moderate Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Empire Neurology, PC
1309
mi
from
Latham, NY
Click here to add this to my saved trials